These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 30940536)

  • 1. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.
    Laprairie RB; Bagher AM; Rourke JL; Zrein A; Cairns EA; Kelly MEM; Sinal CJ; Kulkarni PM; Thakur GA; Denovan-Wright EM
    Neuropharmacology; 2019 Jun; 151():1-12. PubMed ID: 30940536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
    Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
    Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.
    Laprairie RB; Kulkarni PM; Deschamps JR; Kelly MEM; Janero DR; Cascio MG; Stevenson LA; Pertwee RG; Kenakin TP; Denovan-Wright EM; Thakur GA
    ACS Chem Neurosci; 2017 Jun; 8(6):1188-1203. PubMed ID: 28103441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enantiomer-specific positive allosteric modulation of CB
    Mitjavila J; Yin D; Kulkarni PM; Zanato C; Thakur GA; Ross R; Greig I; Mackie K; Straiker A
    Pharmacol Res; 2018 Mar; 129():475-481. PubMed ID: 29158048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methods to Quantify Cell Signaling and GPCR Receptor Ligand Bias: Characterization of Drugs that Target the Endocannabinoid Receptors in Huntington's Disease.
    Bagher AM; Laprairie RB; Kelly MEM; Denovan-Wright EM
    Methods Mol Biol; 2018; 1780():549-571. PubMed ID: 29856035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation.
    Thapa D; Cairns EA; Szczesniak AM; Kulkarni PM; Straiker AJ; Thakur GA; Kelly MEM
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31968549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.
    Slivicki RA; Xu Z; Kulkarni PM; Pertwee RG; Mackie K; Thakur GA; Hohmann AG
    Biol Psychiatry; 2018 Nov; 84(10):722-733. PubMed ID: 28823711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice.
    Dowie MJ; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
    Neuroscience; 2010 Sep; 170(1):324-36. PubMed ID: 20600638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The In Vivo Effects of the CB
    Cairns EA; Szczesniak AM; Straiker AJ; Kulkarni PM; Pertwee RG; Thakur GA; Baldridge WH; Kelly MEM
    J Ocul Pharmacol Ther; 2017 Oct; 33(8):582-590. PubMed ID: 28719234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model.
    Sepers MD; Smith-Dijak A; LeDue J; Kolodziejczyk K; Mackie K; Raymond LA
    J Neurosci; 2018 Jan; 38(3):544-554. PubMed ID: 29192125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients.
    Laprairie RB; Warford JR; Hutchings S; Robertson GS; Kelly ME; Denovan-Wright EM
    J Neuroimmunol; 2014 Feb; 267(1-2):61-72. PubMed ID: 24360910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure.
    Garai S; Schaffer PC; Laprairie RB; Janero DR; Pertwee RG; Straiker A; Thakur GA
    Bioorg Med Chem; 2021 Nov; 50():116421. PubMed ID: 34634617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive allosteric modulation of the cannabinoid CB
    Green HM; Manning JJ; Greig IR; Ross RA; Finlay DB; Glass M
    Br J Pharmacol; 2024 Oct; 181(19):3642-3662. PubMed ID: 38831545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive allosteric modulation of type 1 cannabinoid receptors reduces spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg.
    Roebuck AJ; Greba Q; Smolyakova AM; Alaverdashvili M; Marks WN; Garai S; Baglot SL; Petrie G; Cain SM; Snutch TP; Thakur GA; Hill MN; Howland JG; Laprairie RB
    Neuropharmacology; 2021 Jun; 190():108553. PubMed ID: 33845076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Cannabinoid Receptor Type 1 Positive Allosteric Modulator ZCZ011 Attenuates Naloxone-Precipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice.
    Dodu JC; Moncayo RK; Damaj MI; Schlosburg JE; Akbarali HI; O'Brien LD; Kendall DA; Wu Z; Lu D; Lichtman AH
    J Pharmacol Exp Ther; 2022 Jan; 380(1):1-14. PubMed ID: 34625464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease.
    Doria JG; Silva FR; de Souza JM; Vieira LB; Carvalho TG; Reis HJ; Pereira GS; Dobransky T; Ribeiro FM
    Br J Pharmacol; 2013 Jun; 169(4):909-21. PubMed ID: 23489026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.
    Kedaigle AJ; Reidling JC; Lim RG; Adam M; Wu J; Wassie B; Stocksdale JT; Casale MS; Fraenkel E; Thompson LM
    Hum Mol Genet; 2020 Jan; 29(2):202-215. PubMed ID: 31696228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice.
    Ooms M; Rietjens R; Rangarajan JR; Vunckx K; Valdeolivas S; Maes F; Himmelreich U; Fernandez-Ruiz J; Bormans G; Van Laere K; Casteels C
    Neurobiol Aging; 2014 Dec; 35(12):2858-2869. PubMed ID: 25018107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CB
    Trexler KR; Eckard ML; Kinsey SG
    Pharmacol Biochem Behav; 2019 Feb; 177():27-33. PubMed ID: 30597181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.
    Laprairie RB; Bagher AM; Kelly ME; Denovan-Wright EM
    Mol Pharmacol; 2016 Mar; 89(3):364-75. PubMed ID: 26700564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.